- BuChE-IDO1 inhibitor as well as preparation method and application thereof
-
The invention relates to the field of medicines, and particularly discloses a BuChE-IDO1 inhibitor as well as a preparation method and application thereof. The 7-chlorine-3-substituted benzothiophene part of sertaconazole is chemically modified, the influence of the 7-chlorine-3-substituted benzothiophene part of sertaconazole on the in-vitro inhibitory activity of AChE, BuChE and IDO1 is explored, the target compound is further optimized, and the technical problems that an existing BuChE-IDO1 inhibitor is poor in pertinence and safety are solved. What is explored is that an appropriate substituent group introduced to a 2-benzothiazole ring can form additional interaction with surrounding amino acids and heme iron, so that the binding affinity of the analogue with BuChE and IDO1 is increased, and a new idea is broadened for more efficient and targeted treatment of advanced AD diseases.
- -
-
Paragraph 0031-0033; 0037-0039
(2021/04/26)
-
- Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies
-
In our effort towards the identification of novel BuChE-IDO1 dual-targeted inhibitor for the treatment of Alzheimer's disease (AD), sertaconazole was identified through a combination of structure-based virtual screening followed by MM-GBSA rescoring. Preliminary chemical optimization was performed to develop more potent and selective sertaconazole analogues. In consideration of the selectivity and the inhibitory activity against target proteins, compounds 5c and 5d were selected for the next study. Further modification of compound 5c led to the generation of compound 10g with notably improved selectivity towards BuChE versus AChE. The present study provided us with a good starting point to further design potent and selective BuChE-IDO1 inhibitors, which may benefit the treatment of late stage AD.
- Zhou, You,Lu, Xin,Du, Chenxi,Liu, Yijun,Wang, Yifan,Hong, Kwon Ho,Chen, Yao,Sun, Haopeng
-
-
- One pot synthesis of α-N-heteroaryl ketone derivatives from aryl ketones using aqueous NaICl2
-
A simple and efficient method for the synthesis of α-heteroaryl ketones from aryl ketones and amine using aqueous sodium dichloroiodate is established. This method is mild, operationally simple, has a short reaction time, and easy workup procedure to afford the corresponding α-N-heteroaryl ketone derivatives in moderate to good yield.
- Ghodse, Shrikant M.,Hatvate, Navnath T.,Telvekar, Vikas N.
-
supporting information
(2021/12/08)
-
- Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections
-
A series of selenium-containing miconazole derivatives were identified as potent antifungal drugs in our previous study. Representative compound A03 (MIC = 0.01 μg/mL against C.alb. 5314) proved efficacious in inhibiting the growth of fungal pathogens. However, further study showed lead compound A03 exhibited potential hemolysis, significant cytotoxic effect and unfavorable metabolic stability and was therefore modified to overcome these drawbacks. In this article, the further optimization of selenium-containing miconazole derivatives resulted in the discovery of similarly potent compound B17 (MIC = 0.02 μg/mL against C.alb. 5314), exhibiting a superior pharmacological profile with decreased rate of metabolism, cytotoxic effect and hemolysis. Furthermore, compound B17 showed fungicidal activity against Candida albicans and significant effects on the treatment of resistant Candida albicans infections. Meanwhile, compound B17 not only could reduce the ergosterol biosynthesis pathway by inhibiting CYP51, but also inhibited biofilm formation. More importantly, compound B17 also shows promising in vivo efficacy after intraperitoneal injection and the PK study of compound B17 was evaluated. In addition, molecular docking studies provide a model for the interaction between the compound B17 and the CYP51 protein. Overall, we believe that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections.
- Xu, Hang,Yan, Zhong-zuo,Guo, Meng-bi,An, Ran,Wang, Xin,Zhang, Rui,Mou, Yan-hua,Hou, Zhuang,Guo, Chun
-
-
- Design and Synthesis of Tetrazole- And Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors
-
Itraconazole, a widely used antifungal drug, was found to possess antiangiogenic activity and is currently undergoing multiple clinical trials for the treatment of different types of cancer. However, it suffers from extremely low solubility and strong interactions with many drugs through inhibition of CYP3A4, limiting its potential as a new antiangiogenic and anticancer drug. To address these issues, a series of analogs in which the phenyl group is replaced with pyridine or fluorine-substituted benzene was synthesized. Among them the pyridine- and tetrazole-containing compound 24 has significantly improved solubility and reduced CYP3A4 inhibition compared to itraconazole. Similar to itraconazole, compound 24 inhibited the AMPK/mTOR signaling axis and the glycosylation of VEGFR2. It also induced cholesterol accumulation in the endolysosome and demonstrated binding to the sterol-sensing domain of NPC1 in a simulation study. These results suggested that compound 24 may serve as an attractive candidate for the development of a new generation of antiangiogenic drug.
- Cheng, Zhiqiang,Head, Sarah A.,Li, Ruo-Jing,Li, Yingjun,Liu, Jun O.,Liu, Wukun,Pasunooti, Kalyan Kumar,Peng, Hanjing,Shi, Wei Q.
-
p. 1111 - 1117
(2020/07/04)
-
- Design, synthesis, and biological evaluation of novel miconazole analogues containing selenium as potent antifungal agents
-
Herein, based on the theory of bioisosterism, a series of novel miconazole analogues containing selenium were designed, synthesized and their inhibitory effects on thirteen strains of pathogenic fungi were evaluated. It is especially encouraging that all the novel target compounds displayed significant antifungal activities against all tested strains. Furthermore, all the target compounds showed excellent inhibitory effects on fluconazole-resistant fungi. Subsequently, preliminary mechanistic studies indicated that the representative compound A03 had a strong inhibitory effect on C.alb. CYP51. Moreover, the target compounds could prevent the formation of fungi biofilms. Further hemolysis test verified that potential compounds had higher safety than miconazole. In addition, molecular docking study provided the interaction modes between the target compounds and C.alb. CYP51. These results strongly suggested that some target compounds are promising as novel antifungal drugs.
- An, Ran,Guo, Chun,Guo, Meng-bi,Hou, Zhuang,Mou, Yan-hua,Su, Xin,Xu, Hang
-
-
- Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues
-
Dysregulation of the hedgehog (Hh) signaling pathway is associated with cancer occurrence and development in various malignancies. Previous structure-activity relationships (SAR) studies have provided potent Itraconazole (ITZ) analogues as Hh pathway antagonists. To further expand on our SAR for the ITZ scaffold, we synthesized and evaluated a series of compounds focused on replacing the triazole. Our results demonstrate that the triazole region is amenable to modification to a variety of different moieties; with a single methyl group representing the most favorable substituent. In addition, nonpolar substituents were more active than polar substituents. These SAR results provide valuable insight into the continued exploration of ITZ analogues as Hh pathway antagonists.
- Wen, Jiachen,Teske, Kelly A.,Kyle Hadden
-
supporting information
(2020/01/02)
-
- Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles
-
Azole antifungals inhibit the biosynthesis of ergosterol, the fungal equivalent of cholesterol in mammalian cells. Here we report an investigation of the activity of coumarin-substituted azole antifungals. Screening against a panel of Candida pathogens, including a mutant lacking CYP51, the target of antifungal azoles, revealed that this enzyme is inhibited by triazole-based antifungals, whereas imidazole-based derivatives have more than one mode of action. The imidazole-bearing antifungals more effectively reduced trailing growth associated with persistence and/or recurrence of fungal infections than triazole-based derivatives. The imidazole derivatives were more toxic to mammalian cells and more potently inhibited the activity of CYP3A4, which is one of the main causes of azole toxicity. Using live cell imaging, we showed that regardless of the type of azole ring fluorescent 7-diethylaminocoumarin-based azoles localized to the endoplasmic reticulum, the organelle that harbors CYP51. This study suggests that the coumarin is a promising scaffold for development of novel azole-based antifungals that effectively localize to the fungal cell endoplasmic reticulum.
- Elias, Rebecca,Benhamou, Raphael I.,Jaber, Qais Z.,Dorot, Orly,Zada, Sivan Louzoun,Oved,Pichinuk, Edward,Fridman
-
supporting information
p. 779 - 790
(2019/07/10)
-
- Preparation method of ketoconazole
-
The invention belongs to the technical field of medicine synthesis and in particular relates to a preparation method of ketoconazole. The preparation method of the ketoconazole, provided by the invention, comprises the following step: S101: enabling a compound shown as a formula I and a compound shown as a formula II to be mixed for reaction in an acidic medium to obtain the ketoconazole. According to the preparation method of the ketoconazole, the steric hindrance of the compound shown as the formula I and the compound shown as the formula II is great, so that the cis-trans selectivity of 1,3-dioxolame formed by reaction of the compound shown as the formula I and the compound shown as the formula II is remarkably improved, and furthermore, a benzoyl removing step is omitted; finally, theproduction period of the ketoconazole is shortened and the cost is reduced; meanwhile, the utilization of dangerous substances including bromine liquid and the like is reduced; the technical defects in the prior art that steps for synthesizing the ketoconazole is more and the yield and the purity are low are overcome.
- -
-
Paragraph 0037; 0044; 0047; 0049
(2018/04/03)
-
- Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease
-
In our endeavor towards the development of potent multi-target ligands for the treatment of Alzheimer's disease, miconazole was identified to show BuChE-IDO1 dual-target inhibitory effects. Morris water maze test indicated that miconazole obviously ameliorated the cognitive function impaired by scopolamine. Furthermore, it showed good safety in primary hepatotoxicity evaluation. Based on these results, we designed, synthesized, and evaluated a series of miconazole derivatives as BuChE-IDO1 dual-target inhibitors. Out of the 12 compounds, 5i and 5j exhibited the best potency in enzymatic evaluation, thus were selected for subsequent behavioral study, in which the two compounds exerted much improved effect than tacrine. Meanwhile, 5i and 5j displayed no apparent hepatotoxicity. The results suggest that miconazole analogue offers an attractive starting point for further development of new BuChE-IDO1 dual-target inhibitors against Alzheimer's disease.
- Lu, Xin,He, Si-yu,Li, Qi,Yang, Hongyu,Jiang, Xueyang,Lin, Hongzhi,Chen, Yao,Qu, Wei,Feng, Feng,Bian, Yaoyao,Zhou, You,Sun, Haopeng
-
p. 1665 - 1674
(2018/02/23)
-
- Sterol 14α-Demethylase Structure-Based Design of VNI ((R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives to Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis
-
Because of the increase in the number of immunocompromised patients, the incidence of invasive fungal infections is growing, but the treatment efficiency remains unacceptably low. The most potent clinical systemic antifungals (azoles) are the derivatives of two scaffolds: ketoconazole and fluconazole. Being the safest antifungal drugs, they still have shortcomings, mainly because of pharmacokinetics and resistance. Here, we report the successful use of the target fungal enzyme, sterol 14α-demethylase (CYP51), for structure-based design of novel antifungal drug candidates by minor modifications of VNI [(R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)], an inhibitor of protozoan CYP51 that cures Chagas disease. The synthesis of fungi-oriented VNI derivatives, analysis of their potencies to inhibit CYP51s from two major fungal pathogens (Aspergillus fumigatus and Candida albicans), microsomal stability, effects in fungal cells, and structural characterization of A. fumigatus CYP51 in complexes with the most potent compound are described, offering a new antifungal drug scaffold and outlining directions for its further optimization.
- Friggeri, Laura,Hargrove, Tatiana Y.,Wawrzak, Zdzislaw,Blobaum, Anna L.,Rachakonda, Girish,Lindsley, Craig W.,Villalta, Fernando,Nes, W. David,Botta, Maurizio,Guengerich, F. Peter,Lepesheva, Galina I.
-
p. 5679 - 5691
(2018/06/22)
-
- Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition
-
Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 μM). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.
- Li, Yingjun,Pasunooti, Kalyan Kumar,Li, Ruo-Jing,Liu, Wukun,Head, Sarah A.,Shi, Wei Q.,Liu, Jun O.
-
supporting information
p. 11158 - 11168
(2019/01/08)
-
- Anti-staphylococcal biofilm activity of miconazoctylium bromide
-
We designed and synthesized miconazole analogues containing a substituted imidazolium moiety. The structural modification of the miconazole led to a compound with high potency to prevent the formation and disrupt bacterial biofilms, as a result of accumulation in the biofilm matrix, permeabilization of the bacterial membrane and generation of reactive oxygen species in the cytoplasm.
- Tessier, Jérémie,Golmohamadi, Mahmood,Wilkinson, Kevin J.,Schmitzer, Andreea R.
-
supporting information
p. 4288 - 4294
(2018/06/22)
-
- Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3
-
In an effort to identify new antidiabetic agents, we have discovered a novel family of (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3). We developed efficient synthetic routes to explore a wide variety of substitution patterns and convergently access a diverse array of analogues. Compound 1 (CHIR-911, CT-99021, or CHIR-73911) emerged from an exploration of heterocycles at the C-5 position, phenyl groups at C-4, and a variety of differently substituted linker and aminopyridine moieties attached at the C-2 position. These compounds exhibited GSK3 IC50s in the low nanomolar range and excellent selectivity. They activate glycogen synthase in insulin receptor-expressing CHO-IR cells and primary rat hepatocytes. Evaluation of lead compounds 1 and 2 (CHIR-611 or CT-98014) in rodent models of type 2 diabetes revealed that single oral doses lowered hyperglycemia within 60 min, enhanced insulin-stimulated glucose transport, and improved glucose disposal without increasing insulin levels.
- Wagman, Allan S.,Boyce, Rustum S.,Brown, Sean P.,Fang, Eric,Goff, Dane,Jansen, Johanna M.,Le, Vincent P.,Levine, Barry H.,Ng, Simon C.,Ni, Zhi-Jie,Nuss, John M.,Pfister, Keith B.,Ramurthy, Savithri,Renhowe, Paul A.,Ring, David B.,Shu, Wei,Subramanian, Sharadha,Zhou, Xiaohui A.,Shafer, Cynthia M.,Harrison, Stephen D.,Johnson, Kirk W.,Bussiere, Dirksen E.
-
p. 8482 - 8514
(2017/11/03)
-
- Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo
-
UNC-51-like kinase 1 (ULK1) is well-known to initiate autophagy, and the downregulation of ULK1 has been found in most breast cancer tissues. Thus, the activation of ULK1-modulated autophagy could be a promising strategy for breast cancer therapy. In this study, we found that ULK1 was remarkably downregulated in breast cancer tissue samples by The Cancer Genome Atlas (TCGA) analysis and tissue microarray (TMA) analysis, especially in triple negative breast cancer (TNBC). To design a ULK1 agonist, we integrated in silico screening and chemical synthesis to acquire a series of small molecule candidates. After rounds of kinase and anti-proliferative activity screening, we discovered the small molecule, LYN-1604, to be the best candidate for a ULK1 agonist. Additionally, we identified that three amino acid residues (LYS50, LEU53, and TYR89) were key to the activation site of LYN-1604 and ULK1 by site-directed mutagenesis and biochemical assays. Subsequently, we demonstrated that LYN-1604 could induce cell death, associated with autophagy by the ULK complex (ULK1-mATG13-FIP200-ATG101) in MDA-MB-231 cells. To further explore LYN-1604-induced autophagic mechanisms, we found some potential ULK1 interactors, such as ATF3, RAD21, and caspase3, by performing comparative microarray analysis. Intriguingly, we found that LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. Moreover, we demonstrated that LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo; thus making this ULK1 agonist a novel potential small-molecule drug candidate for future TNBC therapy.
- Zhang, Lan,Fu, Leilei,Zhang, Shouyue,Zhang, Jin,Zhao, Yuqian,Zheng, Yaxin,He, Gu,Yang, Shengyong,Ouyang, Liang,Liu, Bo
-
p. 2687 - 2701
(2017/04/06)
-
- ULK1 micromolecule stimulant and application of stimulant in antitumor drug
-
The invention relates to an ULK1 micromolecule stimulant and an application of the stimulant in an antitumor drug, which belong to the technical field of antitumor pharmacy. The invention provides a compound taken as the ULK1 micromolecule stimulant. The compound comprises the compound shown in a specification or its pharmaceutically acceptable salt. The compound or its pharmaceutically acceptable salt can be taken as the ULK1 stimulant, has certain antineoplastic activity, and effectively inhibits the growth of the cancer cells. The compound has obvious inhibition effect for a plurality of tumor cells, especially breast cancer cells.
- -
-
Paragraph 0096; 0097; 0098; 0099
(2017/07/31)
-
- Discovery of in vitro antitubercular agents through in silico ligand-based approaches
-
The development of new anti-tubercular agents represents a constant challenge mostly due to the insurgency of resistance to the currently available drugs. In this study, a set of 60 molecules were selected by screening the Asinex and the ZINC collections and an in house library by means of in silico ligand-based approaches. Biological assays in Mycobacterium tuberculosis H37Ra ATCC 25177 strain highlighted (±)-1-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl-4-(3,4-dichlorophenyl)piperazine-1-carboxylate (5i) and 3-(4-chlorophenyl)-5-(2,4-dimethylpyrimidin-5-yl)-2-methylpyrazolo[1.5-a]pyrimidin-7(4H)-one (42) as the most potent compounds, having a Minimum Inhibitory Concentration (MIC) of 4 and 2 μg/4g/mL respectively. These molecules represent a good starting point for further optimization of effective anti-TB agents.
- De Vita, Daniela,Pandolfi, Fabiana,Cirilli, Roberto,Scipione, Luigi,Di Santo, Roberto,Friggeri, Laura,Mori, Mattia,Fiorucci, Diego,Maccari, Giorgio,Christopher, Robert Selwyne Arul,Zamperini, Claudio,Pau, Valentina,De Logu, Alessandro,Tortorella, Silvano,Botta, Maurizio
-
p. 169 - 180
(2016/06/09)
-
- Synthesis of imidazole aromatic alcohol derivatives and the preparation thereof
-
The invention discloses synthesis of imidazole aromatic alcohol derivatives and preparations of the imidazole aromatic alcohol derivatives. The imidazole aromatic alcohol derivatives are 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl-1H-imidzole nitrate, 1-[2-[(4-chlorphenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidzole, 1-[2-(4-chlorphenyl)-2-(2,6-dichlorophenyl methoxy)ethyl]-1H-imidzole nitrate, 1-[2-(2,4-dichlorophenyl)-2-{[4-phenyl sulfo]phenyl]methoxy]ethyl}-1H-imidzole nitrate, 1-[2-[(2-chlorine-3-thiophene methoxy)]-2-(2,4-dichlorophenyl)]ethyl imidazole, 1-[2-(7-cholorbenzo[b]thiophene-3-group)methoxy-2-(2,4-dichlorophenyl)ethyl]-1H-imidzole nitrate and (2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidzole nitrate. The synthetic route comprises the following steps of: performing N-alkylation reaction on halogenated acetophenone and imidazole to reduce carbonyl into corresponding alcohol; performing O-alkylation reaction on the corresponding benzyl halide in the presence of a phase transfer catalyst; reacting with acid to form a salt so as to obtain a target compound; and directly or indirectly adding a pharmaceutically acceptable excipient into the target compound by using the conventional process to prepare clinically acceptable formulations such as tablets, soft capsules, suppositories, emulsifiable paste, ointment, gel, liniments, lotion, aerosol and spray so as to exert curative effect better.
- -
-
Paragraph 0013; 0014
(2016/10/08)
-
- Substituted imidazole-1-vinyl compound and use thereof
-
The invention relates to a substituted imidazole-1-ethylene compound as well as a preparation and an application thereof. The substituted imidazole-1-ethylene compound is a compound shown as a formula I, or salts thereof formed with medicinal acids or bases. According to the antifungal activity test performed on eight clinical fungi by the compound provided in the invention, a good fungus killing effect is achieved. The compound can serve as a novel broad-spectrum antifungal activity compound and is developed into antifungal medicines, disinfectants or feed additives.
- -
-
Paragraph 0056; 0118-0121
(2016/10/27)
-
- Structural basis for rational design of inhibitors targeting Trypanosoma cruzi Sterol 14α-demethylase: Two regions of the enzyme molecule potentiate its inhibition
-
Chagas disease, which was once thought to be confined to endemic regions of Latin America, has now gone global, becoming a new worldwide challenge with no cure available. The disease is caused by the protozoan parasite Trypanosoma cruzi, which depends on the production of endogenous sterols, and therefore can be blocked by sterol 14α-demethylase (CYP51) inhibitors. Here we explore the spectral binding parameters, inhibitory effects on T. cruzi CYP51 activity, and antiparasitic potencies of a new set of β-phenyl imidazoles. Comparative structural characterization of the T. cruzi CYP51 complexes with the three most potent inhibitors reveals two opposite binding modes of the compounds ((R)-6, EC50 = 1.2 nM, vs (S)-2/(S)-3, EC50 = 1.0/5.5 nM) and suggests the entrance into the CYP51 substrate access channel and the heme propionate-supporting ceiling of the binding cavity as two distinct areas of the protein that enhance molecular recognition and therefore could be used for the development of more effective antiparasitic drugs.
- Friggeri, Laura,Hargrove, Tatiana Y.,Rachakonda, Girish,Williams, Amanda D.,Wawrzak, Zdzislaw,Di Santo, Roberto,De Vita, Daniela,Waterman, Michael R.,Tortorella, Silvano,Villalta, Fernando,Lepesheva, Galina I.
-
p. 6704 - 6717
(2014/09/29)
-
- Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
-
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathological immune escape, such as cancer. Here, we describe a robust and sensitive high-throughput screen (HTS) for IDO1 inhibitors using the Prestwick Chemical Library of 1200 FDA-approved drugs and the Maybridge HitFinder Collection of 14,000 small molecules. Of the 60 hits selected for follow-up studies, 14 displayed IC50 values below 20 μM under the secondary assay conditions, and 4 showed an activity in cellular tests. In view of the high attrition rate we used both experimental and computational techniques to identify and to characterize compounds inhibiting IDO1 through unspecific inhibition mechanisms such as chemical reactivity, redox cycling, or aggregation. One specific IDO1 inhibitor scaffold, the imidazole antifungal agents, was chosen for rational structure-based lead optimization, which led to more soluble and smaller compounds with micromolar activity.
- R?hrig, Ute F.,Majjigapu, Somi Reddy,Chambon, Marc,Bron, Sylvian,Pilotte, Luc,Colau, Didier,Van Den Eynde, Beno?t J.,Turcatti, Gerardo,Vogel, Pierre,Zoete, Vincent,Michielin, Olivier
-
p. 284 - 301
(2014/08/05)
-
- Asymmetric chemoenzymatic synthesis of miconazole and econazole enantiomers. the importance of chirality in their biological evaluation
-
A simple and novel chemoenzymatic route has been applied for the first time in the synthesis of miconazole and econazole single enantiomers. Lipases and oxidoreductases have been tested in stereoselective processes; the best results were attained with oxidoreductases for the introduction of chirality in an adequate intermediate. The behaviors of a series of ketones and racemic alcohols in bioreductions and acetylation procedures, respectively, have been investigated; the best results were found with alcohol dehydrogenases A and T, which allowed the production of (R)-2-chloro-1-(2,4-dichlorophenyl)ethanol in enantiopure form under very mild reaction conditions. Final chemical modifications have been performed in order to isolate the target fungicides miconazole and econazole both as racemates and as single enantiomers. Biological evaluation of the racemates and single enantiomers has shown remarkable differences against the growth of several microorganisms; while (R)-miconazole seemed to account for most of the biological activity of racemic miconazole on all the strains tested, both enantiomers of econazole showed considerable biological activities. In this manner, (R)-econazole showed higher values against Candida krusei, while higher values were observed for (S)-econazole against Cryptococcus neoformans, Penicillium chrysogenum, and Aspergillus niger.
- Mangas-Sanchez, Juan,Busto, Eduardo,Gotor-Fernandez, Vicente,Malpartida, Francisco,Gotor, Vicente
-
supporting information; experimental part
p. 2115 - 2122
(2011/05/19)
-
- Heme oxygenase inhibition by 1-Aryl-2-(1H-imidazol-1-yl/1H-1,2,4-triazol-1- yl)ethanones and their derivatives
-
Previous studies by our research group have been concerned with the design of selective inhibitors of heme oxygenases (HO-1 and HO-2). The majority of these were based on a four-carbon linkage of an azole, usually an imidazole, and an aromatic moiety. In the present study, we designed and synthesized a series of inhibition candidates containing a shorter linkage between these groups, specifically, a series of 1-aryl-2-(1H-imidazol-1-yl/1H-1,2,4-triazol-1-yl) ethanones and their derivatives. As regards HO-1 inhibition, the aromatic moieties yielding best results were found to be halogen-substituted residues such as 3-bromophenyl, 4-bromophenyl, and 3,4-dichlorophenyl, or hydrocarbon residues such as 2-naphthyl, 4-biphenyl, 4-benzylphenyl, and 4-(2-phenethyl)phenyl. Among the imidazole-ketones, five (36-39, and 44) were found to be very potent (IC5050 in favor of HO-1. In the case of the azole-dioxolanes, two of them (80 and 85), each possessing a 2-naphthyl moiety, were found to be particularly potent and selective HO-1 inhibitors. Three non-carbonyl analogues (87, 89, and 91) of 1-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethanone were found to be good inhibitors of HO-1. For the first time in our studies, two azole-based inhibitors (37 and 39) were found to exhibit a modest selectivity index in favor of HO-2. The present study has revealed additional candidates based on inhibition of heme oxygenases for potentially useful pharmacological and therapeutic applications.
- Roman, Gheorghe,Vlahakis, Jason Z.,Vukomanovic, Dragic,Nakatsu, Kanji,Szarek, Walter A.
-
experimental part
p. 1541 - 1555
(2011/11/29)
-
- Asymmetric synthesis and stereochemical structure-activity relationship of (R)- and (S)-8-[1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethoxy] octanoic acid heptyl ester, a potent inhibitor of allene oxide synthase
-
The preparation of both enantiomers of 8-[1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethoxy] octanoic acid heptyl ester (JM-8686), a potent inhibitor of allene oxide synthase, has been achieved using 2,4-dichlorophenacyl bromide as a starting material. The key step was the asymmetric reduction of 1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethanone with chiral BINAL-H. The products were purified by chiral high-performance liquid chromatography (HPLC) to afford pure (R)-JM-8686 and (S)-JM-8686. The inhibitory activities and binding affinities of these enantiomers toward allene oxide synthase were determined. We found that the inhibition potency of (R)-JM-8686 is approximately 200 times greater than that of (S)-JM-8686, with IC50 values of approximately 5 ± 0.2 nM and 950 ± 18 nM, respectively. The dissociation constants of (R)-JM-8686 and (S)-JM-8686 with respect to the recombinant allene oxide synthase were approximately 1.4 ± 0.3 μM and 4.8 ± 0.6 μM, respectively.
- Oh, Keimei,Shimura, Yoichiro,Ishikawa, Kyoko,Ito, Yudai,Asami, Tadao,Murofushi, Noboru,Yoshizawa, Yuko
-
p. 1090 - 1095
(2008/09/19)
-
- Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives
-
1-(3,5-Diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives were synthesized and tested for their in vitro antifungal and antimycobacterial activities. These imidazole derivatives showed an excellent antifungal activity against a clinical strain of Candida albicans and an interesting antitubercular activity againstMycobacterium tuberculosis H37Rv reference strain.
- Zampieri, Daniele,Mamolo, Maria Grazia,Laurini, Erik,Scialino, Giuditta,Banfi, Elena,Vio, Luciano
-
p. 4516 - 4522
(2008/09/21)
-
- The "reverse-tethered" ruthenium (II) catalyst for asymmetric transfer hydrogenation: Further applications
-
The attachment of a tethering group from the basic nitrogen atom to the arene ligand of a ruthenium(II) catalyst greatly improves its ability to catalyze asymmetric transfer hydrogenation (ATH) reactions. In this paper, we describe further applications of this versatile system to an extended substrate range.
- Morris, David J.,Hayes, Aidan M.,Wills, Martin
-
p. 7035 - 7044
(2007/10/03)
-
- An efficient catalytic asymmetric route to 1-aryl-2-imidazol-1-yl-ethanols
-
The asymmetric hydrogenation of 1-aryl-2-imidazol-1-yl-ethanones offers a concise route to homochiral 1-aryl-2-imidazol-1-yl-ethanols. Catalytic asymmetric transfer hydrogenation with formic acid using [(R,R)-TsDPEN] Ru(Cymene)Cl as precatalyst was shown to be effective in this transformation. Preliminary process development showed that the hydrogenation could be carried out under mild conditions at a molar substrate-to-catalyst (S/C) ratio of 1000-2000.
- Lennon, Ian C.,Ramsden, James A.
-
p. 110 - 112
(2012/12/24)
-
- Copper carbenoid mediated N-alkylation of imidazoles and its use in a novel synthesis of bifonazole
-
1H-Imidazoles are readily N-alkylated by a Cu(acac)2 mediated reaction with α-diazocarbonyl compounds or with diazoalkanes generated in situ from the corresponding p-toluensulfonyl hydrazones. The antifungal agent bifonazole was prepared by the latter method. Graphical Abstract.
- Cuevas-Ya?ez, Erick,Serrano, Juan Manuel,Huerta, Gloria,Muchowski, Joseph M.,Cruz-Almanza, Raymundo
-
p. 9391 - 9396
(2007/10/03)
-
- N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase
-
A series of substituted guanidine derivatives were prepared and evaluated as potent and selective inhibitors of mitochondrial F1F0 ATP hydrolase. The initial thiourethane derived lead molecules possessed intriguing in vitro pharmacological profiles, though contained moieties considered non-drug-like. Analogue synthesis efforts led to compounds with maintained potency and superior physical properties. Small molecules in this series which potently and selectivity inhibit ATP hydrolase and not ATP synthase may have utility as cardioprotective agents.
- Atwal, Karnail S.,Ahmad, Saleem,Ding, Charles Z.,Stein, Philip D.,Lloyd, John,Hamann, Lawrence G.,Green, David W.,Ferrara, Francis N.,Wang, Paulina,Rogers, W. Lynn,Doweyko, Lidia M.,Miller, Arthur V.,Bisaha, Sharon N.,Schmidt, Joan B.,Li, Ling,Yost, Kenneth J.,Lan, Hsi-Jung,Madsen, Cort S.
-
p. 1027 - 1030
(2007/10/03)
-
- Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides
-
The invention concerns novel azole or triazole derivatives of formula (Ia) or (Ib), wherein: X, Ar1, Ar2, Ar3, A, B and R1 are such as defined in the description, the method for preparing same and their use as fungicides.
- -
-
Page/Page column 7
(2010/02/08)
-
- Novel azole or triazole derivatives, method for preparing the same and use thereof as antifungal medicaments
-
The invention concerns novel azole or triazole derivatives of formula (I), wherein: X, Ar1, Ar3, A, R1, R5, R6, R7 and B are such as defined in the description, their preparation method and their use as antifungal medicines.
- -
-
-
- Clean and efficient microwave-solvent-free synthesis of 1-(2′,4′-dichlorophenacyl) azoles
-
Microwave induced N-alkylation of several azoles with 2,2′,4′-trichloroacetophenone (TCA) under solvent-free conditions allowed to obtain the corresponding 1-(2′,4′-dichlorophenacyl) azoles with satisfactory to good selectivities and yields. TGA and DSC measurements were achieved for the synthesized compounds and showed a close relationship between the thermal behavior and the reaction temperature under microwave heating. Non-purely thermal microwave effects were evidenced during the alkylation of pyrazole and 1H-indazole under the selected conditions.
- Pérez, Eduardo R.,Loupy, André,Liagre, Marion,De Guzzi Plepis, Ana M.,Cordeiro, Paulo J.
-
p. 865 - 870
(2007/10/03)
-
- Heterocyclic vinyl ethers
-
The compounds of the formula wherein R signifies halogen or lower alkyl; n signifies 0-3; R1 signifies lower alkyl; cycloalkyl; benzyl optionally substituted by hydroxy, halogen, lower alkoxy or lower alkyl; benzoyl optionally substituted by amino, lower alkyl-amino or di-lower alkylamino; acetyl or cycloalkyl-carbonyl; and signifies an aromatic 5-membered residue which is bonded via a N-atom and which contains further 1-3 N atoms in addition to the linking N atom, as well as their pharmaceutically acceptable salts as therapeutically active substances, especially for the control or prevention of acute and/or chronic neurological disorders.
- -
-
-
- A new series of miconazole analogs: Synthesis and in vitro antifungal and antimycobacterial activities
-
The synthesis and antimicrobial activity of new miconazole analogs are reported. All compounds showed good antimycobacterial activity; some of them were also active against some strains of Candida albicans and Candida sp.. Of the synthesized compounds, two showed good activity both against some strains of Mycobacterium and some strains of Candida. Structure-activity relationships are discussed.
- Fioravanti, Rossella,Biava, Mariangela,Porretta, Giulio Cesare,Lampis, Giorgio,Deidda, Delia,Pompei, Raffaello
-
p. 162 - 175
(2007/10/03)
-
- Synthesis and antifungal activity of novel (1-aryl-2-heterocyclyl)ethylideneaminooxymethyl-substituted dioxolanes
-
A novel series of (1-aryl-2-heterocyclyl)ethylideneaminooxymethyl-substituted dioxolanes IIIa-n were synthesized by condensation of substituted 1,3-dioxolan-4-ylmethyl p-toluenesulfonates 4 with 1-(hydroxyimino)-1-aryl-2-heterocyclylethanes 5.Compounds IIIa-n were found to have effective in vitro antifungal activity when evaluated against the pathogenic fungi Candida albicans, Aspergillus flavus and Fusarium solani with MIC (minimum inhibitory concentration values of 10 μg*ml-1 for IIIa-l and 5 μg*ml-1 for IIIm,n. antifungal activity / 1,3-dioxolane / ethylideneaminooxy / imidazole / 1,2,4-triazole
- Baji, H.,Flammang, M.,Kimny, T.,Gasquez, F.,Compagnon, P. L.,Delcourt, A.
-
p. 617 - 626
(2007/10/02)
-
- Synthesis and 13C NMR Spectra of cis- and trans-methyl>>-1,3-dioxolane-4-methanols
-
Syntheses and 13C nmr spectra of a number of cis and trans 2-(haloaryl)-2--4-(hydroxymethyl)-1,3-dioxolanes are described.The haloaryl groups are 2,4-dichloro, 2,4-difluoro-, 4-chloro- and 4-bromophenyl.In these series, some of the cis compounds become available through crystalline bromo benzoates 5.Separations of some trans isomers are achieved through fractional crystallizations of imidazolyl benzoate nitrates 6.Stereochemical assignments are based primarily on one major 13C chemical shift difference, namely that of C-4 of the 1,3-dioxolane ring, the chemical shift of the trans isomers being 1.0-2.5 ppm downfield from that of the cis isomers.
- Chapman, David R.,Bauer, Ludwig
-
p. 2053 - 2061
(2007/10/02)
-
- 1-[2-(2,4-dichlorophenyl)-2-(4-substituted piperazine)ethyl]-1H-imidazoles having antimycotic and antibacterial activities, pharmaceutical compositions containing them
-
Compounds of formula I STR1 wherein R is a phenyl group; a phenyl group mono- or di-substituted by halogen atoms, methyl, methoxy, nitro, or trifluoromethyl group; or a 2-, 3- or 4-pyridyl group; and pharmaceutically acceptable acid addition salts thereof. Compounds I are prepared by reacting N-substituted piperazines with 1-(2',4'-dichloro-benzoylmetyl)-imidazole, optionally reducing thereafter the resulting enamines. Compounds I have antimycotic and antibacterial activities, higher than those of known comparison drugs.
- -
-
-
- 1-(α-n-Butylthio-2,4-dichlorophenethyl)imidazol-3-yl and fungicidal use thereof
-
This invention relates to thiophenethyl imidazoles and triazoles and their acid addition salts. This invention also relates to their preparation and their use as broad spectrum phytopathogenic fungicides.
- -
-
-